Search

Displaying results 4931 - 4940 of 8698 in total
  1. Drug

    Vasomera

    go.drugbank.com/drugs/DB16498
    Investigational

    Categories: Experimental Unapproved Treatments for COVID-19
  2. Drug

    INO-4800

    go.drugbank.com/drugs/DB15693
    Investigational

    [A214475] A Phase 1 clinical trial for INO-4800 in the U.S. (NCT04336410) was started on April 3, 2020, with an expected completion date of July 2021. … Furthermore, the antibodies produced were capable of inhibiting the binding of SARS-CoV-2 to the ACE2 receptor, which is thought to be critical for host cell entry.

    Categories: Experimental Unapproved Treatments for COVID-19
  3. Drug

    Sifalimumab

    go.drugbank.com/drugs/DB12773
    Investigational

    The levels of interferon-alpha are elevated in many patients with active systemic lupus erythematosus (SLE, or lupus) and other autoimmune disorders, and may be associated with disease activity. … Sifalimumab may suppress the abnormal immune activity associated with lupus by binding to multiple interferon-alpha subtypes seen in the serum of lupus patients.

  4. Drug

    AMT-080

    go.drugbank.com/drugs/DB17846
    Experimental

    AMT-080 is an investigational gene therapy being investigated for the treatment of Duchenne muscular dystrophy.

  5. Drug

    Depreotide

    go.drugbank.com/drugs/DB11628
    ApprovedWithdrawn

    Depreotide is an ingredient in the EMA-withdrawn product NeoSpect.

  6. Drug

    Cannabinor

    go.drugbank.com/drugs/DB05048
    Experimental

    Cannabinor, a synthetic CB2-selective agonist, is in Phase 2 clinical testing as an analgesic.

  7. Drug

    Methoxsalen

    go.drugbank.com/drugs/DB00553
    ApprovedInvestigational

    A naturally occurring furocoumarin compound found in several species of plants, including Psoralea corylifolia. It is a photoactive substance that forms DNA adducts in the presence of ultraviolet A irradiation.

    Categories: Antipsoriatics for Systemic Use, Antipsoriatics for Topical UseProducts: UVADEX 20 Mikrogramm/ml Lösung zur Modifikation einer Blutfraktion, Oxsoralen 20 Mikrogramm/ml-Lösung zur Modifikation einer Blutfraktion
  8. Drug

    Egaptivon pegol

    go.drugbank.com/drugs/DB05202
    Investigational

    Egaptivon pegol, formerly known as ARC1779, is a therapeutic aptamer antagonist of the A1 domain of von Willebrand Factor (vWF), the ligand for receptor glycoprotein 1b on platelets. … Egaptivon pegol is being investigated for the treatment of thrombotic thrombocytopenic purpura and acute coronary syndromes.

  9. Drug

    Methoxamine

    go.drugbank.com/drugs/DB00723
    ApprovedInvestigationalWithdrawn

    An alpha-adrenergic agonist that causes prolonged peripheral vasoconstriction. It has little if any direct effect on the central nervous system.

    Categories: Adrenergic alpha-1 Receptor Agonists
  10. Drug

    GTS-21

    go.drugbank.com/drugs/DB05708
    Investigational

    GTS-21 (also known as DMBX-A), is a novel, small-molecule, orally active and selective alpha-7 nicotinic acetylcholine (nACh) receptor agonist that has demonstrated memory and cognition enhancement activity

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 Substrates